appdb design contest is in progress! Find out more
CoaguSafe - Anticoagulant

CoaguSafe - Anticoagulant

Please note: CoaguSafe is not a substitute for medical advice. CoaguSafe is intended for educational purposes only.

Puzzled by the vast amount of medication interacting with platelet function and coagulation? When do they have to be paused for surgery or anesthesia ? is it safe to stop antithrombotic agents ? Does oral anticoagulation need 'bridging' ?

This app gives you an answer to these questions and is therefore an ideal educational tool.

The covered substances are:
- Oral anticoagulants
- Heparin
- Low molecular weight heparin
- Adenosin diphosphate (ADP) antagonists
- Factor Xa inhibitors
- Thrombin inhibitors
- Cyclooxygenase inhibitors
- Gp IIb/IIIa inhibitors

There are four questions to be answered:
- Can the drug be paused ?
- What intervention requires pausing ?
- How long should you pause ?
- Does oral anticoagulation need 'bridging' ?

The following guidelines can be selected:
- Kantonsspital St. Gallen, Switzeralnd
- Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin (DGAI)
- Österreichische Gesellschaft für Anästhesiologie, Reanimation und Intensivmedizin
- European Society of Anaesthesiology (ESA)
- American Society of Regional Anesthesia (ASRA)

Local recommendations and expert opinion of the following hospitals were used to develop this app:
University Basel, Switzerland
Work done by:
- Miodrag Filipovic
- Manfred Seeberger
- Michael Zellweger

Kantonsspital St. Gallen, Switzerland
Work done by:
- Miodrag Filipovic
- Wolfgang Korte
- Hans Rickli


CoaguSafe was programmed by Thierry Girard in collaboration with and under expert consulting by Miodrag Filipovic.


---------
Disclaimer
---------
The application CoaguSafe is not a substitute for medical advice. CoaguSafe is intended for educational purposes only. While the data may be updated periodically, users should independently check medical literature and package inserts or other sources for the latest information.
Any and all liability arising directly or indirectly from the use of this application is hereby disclaimed. The information herein is provided "as is" and without any warranty expressed or implied. All direct, indirect, special, incidental, consequential or punitive damages arising from any use of this application or data contained herein is disclaimed and excluded.

What's New

Adapted timing and bridging. Printouts and emails are formatted. Update of Information on substance groups including antagonism with Andexanet Alfa and Idarucizumab, respectively.

Screenshots